Lewis C. Cantley

Founder at Agios Pharmaceuticals, Inc.

Lewis C. Cantley

Lewis C. Cantley

Founder at Agios Pharmaceuticals, Inc.

Overview
Career Highlights

Petra Pharma Corp.
Agios Pharmaceuticals, Inc.

RelSci Relationships

9165

Number of Boards

9

Birthday

1949

Age

71

Number of Awards

6

Contact Data
Trying to get in touch with Lewis C. Cantley? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Lewis C. Cantley likely has professional access to. A relationship does not necessarily indicate a personal connection.

Provost Medl Affrs & Dean at Cornell University

Relationship likelihood: Strong

President & Chief Executive Officer at Dana-Farber Cancer Institute, Inc.

Relationship likelihood: Strong

General Partner at GV Management Co. LLC

Relationship likelihood: Strong

Interim President, Cornell University at Cornell University - Weill Cornell Medical College

Relationship likelihood: Strong

Co-Founder at Agios Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder at Agios Pharmaceuticals, Inc.

Relationship likelihood: Strong

Scientific Founder at Blueprint Medicines Corp.

Relationship likelihood: Strong

Venture Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

SEE Schedule at Methodist Hospital Group

Relationship likelihood: Strong

Former Chief Executive Officer at NFP Corp.

Relationship likelihood: Strong

Paths to Lewis C. Cantley
Potential Connections via
Relationship Science
You
Lewis C. Cantley
Founder at Agios Pharmaceuticals, Inc.
Family Members
Spouse
Chairman & Co-Founder at Vir Biotechnology, Inc.

Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.

Education
BS in Chemistry, summa cum laude
Class of 1971

WEST VIRGINIA WESLEYAN COLLEGE CHALLENGES ITS STUDENTS TO A LIFE-LONG COMMITMENT TO DEVELOP THEIR INTELLECTUAL, ETHICAL, SPIRITUAL, AND LEADERSHIP POTENTIAL AND TO SET AND UPHOLD STANDARDS OF EXCELLENCE. FIRMLY ROOTED IN THE LIBERAL ARTS TRADITION AND CLOSELY RELATED TO THE UNITED METHODIST CHURCH, THE COLLEGE IS A COMMUNITY OF LEARNING BASED ON FUNDAMENTAL PRINCIPLES FORMED AT THE INTERSECTION OF CHRISTIAN FAITH AND LIBERAL EDUCATION: INTELLECTUAL RIGOR, SELF-DISCOVERY, HUMAN DIGNITY, MUTUAL SUPPORT, SOCIAL JUSTICE, SELF-DISCIPLINE, MENTAL AND PHYSICAL WELLNESS, THE APPRECIATION OF DIVERSITY AND THE NATURAL WORLD, AND THE JUDICIOUS USE OF RESOURCES. THE COLLEGE RECOGNIZES AND AFFIRMS ITS INTERDEPENDENCE WITH THE EXTERNAL COMMUNITIES-LOCAL, REGIONAL, NATIONAL, AND GLOBAL-AND ITS COVENANT WITH THE PEOPLE OF WEST VIRGINIA TO SHARE ITS EDUCATIONAL AND CULTURAL RESOURCES.

Ph.D. in Biophysical Chemistry

Founded in 1898, and affiliated with what is now NewYork-Presbyterian Hospital since 1927, Weill Cornell Medical College is among the top-ranked clinical and medical research centers in the country. In addition to offering degrees in medicine, Weill Cornell also has PhD programs in biomedical research and education at the Weill Cornell Graduate School of Medical Sciences, and with neighboring Sloan-Kettering Institute and The Rockefeller University, has established a joint MD-PhD program for students to intensify their pursuit of Weill Cornell's triple mission of education, research, and patient care. Weill Cornell Medical College is divided into 24 basic science and patient care departments that focus on the sciences underlying clinical medicine and/or encompass the study, treatment, and prevention of human diseases. In addition to its affiliation with NewYork-Presbyterian Hospital, Weill Cornell Medical College and the Weill Cornell Graduate School of Medical Sciences maintain major affiliations with Memorial Sloan-Kettering Cancer Center, The Rockefeller University, the Hospital for Special Surgery, as well as with the metropolitan-area institutions that constitute NewYork-Presbyterian Healthcare Network. Weill Cornell Medical College and the Weill Cornell Graduate School of Medical Sciences are accredited by the Liaison Committee for Medical Education of the American Medical Association and the Association of American Medical Colleges.

Memberships
Member
2001 - Current

The National Academy of Sciences (NAS) formed the Committee on International Security and Arms Control (CISAC) in 1980 as a permanent committee to bring the resources of the Academy to bear on critical problems of international security and arms control. CISAC, in the Policy and Global Affairs Division, draws from the nation’s finest scientific, technical, engineering and medical talent to advise the government, contribute to the work of non-governmental organizations, and inform the public about scientific and technical issues related to international security and arms control. CISAC’s work benefits from a rotating membership of distinguished scientists, policy and military experts. The Committee carries out its mandate through a variety of activities that receive financial support from public and private sponsors.

Member
1999 - Current

Founded in 1780, the American Academy of Arts and Sciences is an independent policy research center that conducts multidisciplinary studies of complex and emerging problems. The Academy’s elected members are leaders in the academic disciplines, the arts, business, and public affairs. With a current membership of 4,000 American Fellows and 600 Foreign Honorary Members, the Academy has four major goals: Promoting service and study through analysis of critical social and intellectual issues and the development of practical policy alternatives; Fostering public engagement and the exchange of ideas with meetings, conferences, and symposia bringing diverse perspectives to the examination of issues of common concern; Mentoring a new generation of scholars and thinkers through the Visiting Scholars Program and Hellman Fellowship Program; Honoring excellence by electing to membership men and women in a broad range of disciplines and professions. Click here to learn about our new members. The Academy's headquarters are in Cambridge, Massachusetts. With its geographically diverse membership, it conducts activities in this country and abroad

Fellow
Current

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

Career History
Visiting Professor of Medicine
1978 - 2012

Harvard Medical School (HMS) is the graduate medical school of Harvard University. It is located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts.The school was founded by John Warren on September 19, 1782, with Benjamin Waterhouse, and Aaron Dexter.

Founder
2007 - Current

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Chief, Division of Signal Transduction
2007 - 2012

Beth Israel Deaconess Medical Center (BIDMC) is one of the nation's preeminent academic medical centers. We are committed to excellence in clinical care, biomedical research and education and to the health and wellness of our patients and our communities. Excellence In Clinical Care Beth Israel Deaconess, a major teaching hospital of Harvard Medical School, is a fully integrated medical center providing adult services from cardiology to obstetrics, gastrointestinal disorders to cancer care. Each year U.S. News & World Report ranks BIDMC as a "Best Hospital" in multiple specialties. As national leaders in patient care quality, safety and transparency, we are setting standards in the way health data can be used to improve care and services. We were the first hospital in the country to achieve meaningful use of electronic medical records, meeting a key set of new federal government standards. BIDMC attracts leading clinicians in all medical fields. Our experts not only provide gold standard treatments to help a patient get better, they also help educate the public on disease prevention. BIDMC clinicians feel a responsibility to do more than make patients better when they are sick-they want to help the community stay healthy. Excellence In Research BIDMC is home to a renowned academic research program, where scientific discoveries help to transform medical care. We rank third in the country for National Institutes of Health funding among independent hospitals. With revolutionary advances and therapies happening within our walls, we are a national and international leader in "bench-to-bedside" research. Our patients benefit directly from our dedication to research. At any given moment, more than 300 clinical trials are offered throughout the medical center for those difficult to treat cases, in areas such as cancer, neurology, cardiology and other medical specialties. Excellence In Education BIDMCs 1,250 full-time physicians constitute almost a quarter of Harvard Medical School's faculty. Because of our roots, we are committed to training the next generation of doctors, and have raised medical education to a higher level with a uniquely strong and deep program that enhances our ability to attract top faculty and residents. Learning flourishes within our hallways, as students learn from the best of the best in an open environment that produces leaders of tomorrow. Advancing Care in Communities In pursuit of clinical and research excellence, we have formed partnerships with outstanding community hospitals, specialty care centers and physician practice groups in eastern Massachusetts to give you and your family the convenience of high quality care, close to home. With BIDMC at the core of this network, access to specialty care downtown is always available when appropriate. We are dedicated to providing the right care, at the right time, in the right place. Blending Warmth and Innovation Compassionate nursing is central to your experience here. Our nurses are highly regarded for superb care, kindness and proficiency. Our quality and safety initiatives, second to none, are often held up as a model for other institutions. As a hospital deemed "Most Wired," and "Most Wireless," we are reengineering how to gather, safeguard and utilize health information. Our systems are state-of-the-art and all BIDMC clinicians use centrally hosted electronic medical records. The Heart of Caring You expect excellence in clinical care, research, education and community outreach from a prominent academic medical center. But we believe what makes BIDMC even more remarkable is our spirit. We treat our patients with the utmost respect and compassion, as we would our own family members and friends.

Boards & Committees
Member, Scientific Advisory Board
2007 - Prior

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Member, Advisory Board
Prior

TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma).TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies.In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs.

Member, Scientific Advisory Board
Tenure Unconfirmed

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Director
2012 - Current

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

Member, Board of Directors
Current

The Vallee Foundation was formed by Bert L. and N. Kuggie Vallee as their legacy to the advancement of medical science and medical education. The Foundation stimulates development of interdisciplinary sciences related to human health by promoting interaction between productive scientists worldwide. In addition to the Young Investigator Awards, programs include: Vallee Visiting Professorships for distinguished researchers, international scientific meetings, and a special collaboration with the Lindau Nobel Laureate Meetings.

Member, Board of Overseers
Current

Founded in 1898, and affiliated with what is now NewYork-Presbyterian Hospital since 1927, Weill Cornell Medical College is among the top-ranked clinical and medical research centers in the country. In addition to offering degrees in medicine, Weill Cornell also has PhD programs in biomedical research and education at the Weill Cornell Graduate School of Medical Sciences, and with neighboring Sloan-Kettering Institute and The Rockefeller University, has established a joint MD-PhD program for students to intensify their pursuit of Weill Cornell's triple mission of education, research, and patient care. Weill Cornell Medical College is divided into 24 basic science and patient care departments that focus on the sciences underlying clinical medicine and/or encompass the study, treatment, and prevention of human diseases. In addition to its affiliation with NewYork-Presbyterian Hospital, Weill Cornell Medical College and the Weill Cornell Graduate School of Medical Sciences maintain major affiliations with Memorial Sloan-Kettering Cancer Center, The Rockefeller University, the Hospital for Special Surgery, as well as with the metropolitan-area institutions that constitute NewYork-Presbyterian Healthcare Network. Weill Cornell Medical College and the Weill Cornell Graduate School of Medical Sciences are accredited by the Liaison Committee for Medical Education of the American Medical Association and the Association of American Medical Colleges.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$10K - $25K
2015

The Museum exercises cultural and civic leadership by nurturing a new generation of talent in the arts and humanities; by delivering the works of creators and performers to the public; and by reaching out to involve and serve its community. The collection is at the center of this effort as an inspiring encounter with beauty and art.

$10K - $25K
2014

The Museum exercises cultural and civic leadership by nurturing a new generation of talent in the arts and humanities; by delivering the works of creators and performers to the public; and by reaching out to involve and serve its community. The collection is at the center of this effort as an inspiring encounter with beauty and art.

$10K - $25K
2012

The Museum exercises cultural and civic leadership by nurturing a new generation of talent in the arts and humanities; by delivering the works of creators and performers to the public; and by reaching out to involve and serve its community. The collection is at the center of this effort as an inspiring encounter with beauty and art.

Investments
Details Hidden

Petra Pharma Corp. operates as a drug development company that develops novel small molecules for the treatment of cancer and metabolic diseases. The company was founded by Lewis Clayton Cantley and Nathanael S. Gray in 2016 and is headquartered in New York, NY.

Details Hidden

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Awards & Honors
2013
Breakthrough Prize in Life Sciences
2009
Karolinska Institutet - Rolf Luft Award
2005
Pezcoller Foundation & American Association for Cancer Research - International Award for Cancer Research
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Lewis C. Cantley. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Lewis C. Cantley's profile does not indicate a business or promotional relationship of any kind between RelSci and Lewis C. Cantley.